Home › Therapeutic areas › Neurology › Alzheimer's Disease
Alzheimer's Disease (14 companies)
Companies with an active program in Alzheimer's Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACIU | AC Immune | Neurology Rare | 5 | Phase 3 | $222M | 11 |
| ABOS | Acumen Pharmaceuticals | Neurology | 4 | Phase 2 | $16.2M | 4 |
| AXSM | Axsome Therapeutics | Neurology Rare | 1 | Approved | $6.96B | 15 |
| CGTX | Cognition Therapeutics | Neurology | 1 | Phase 2 | $65.3M | 2 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $338M | 3 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $45.0M | 5 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 3 | Phase 2 | $237M | 12 |
| LGVN | Longeveron | CardiovascularMetabolic+1 Rare | 1 | Phase 2 | $5.8M | 4 |
| MPLT | MapLight Therapeutics | Neurology | 1 | Phase 2 | $385M | 6 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | $3.2M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 1 | NDA Submitted | $2.27B | 6 |
| PMN | ProMIS Neurosciences | Neurology Rare | 1 | Phase 1 | $37.3M | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $87.8M | 5 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $116M | 9 |
No companies match.